Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66,505,186
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
54,841,321
-
Shares change
-
+9,187,233
-
Total reported value, excl. options
-
$97,892,529
-
Value change
-
+$13,518,084
-
Put/Call ratio
-
22%
-
Number of buys
-
38
-
Number of sells
-
-23
-
Price
-
$1.78
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share - Put (RGLS) as of Q2 2024
74 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share - Put as of Q2 2024.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share - Put (RGLS) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,841,321 shares
of 66,505,186 outstanding shares and own 82% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (12,852,654 shares), RA CAPITAL MANAGEMENT, L.P. (6,250,000 shares), Vivo Capital, LLC (5,000,000 shares), Octagon Capital Advisors LP (4,263,701 shares), VANGUARD GROUP INC (4,050,863 shares), BlackRock Inc. (3,968,857 shares), Deep Track Capital, LP (3,262,564 shares), FMR LLC (2,022,600 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,000,000 shares), and Opaleye Management Inc. (1,475,000 shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.